^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hutruo (bermekimab IV)

    i
    Other names: MABp1 IV, CA 18C3 IV, CA-18C3, RA-18C3, T2-18C3, human monoclonal IgG1k antibody, CV-18C3, JNJ-77474462 IV
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    IL-1α inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    [VIRTUAL] A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX). (ASCO 2020)
    We report results of a single site phase 1 trial for an IL-1α antagonist (bermekimab) in combination with nanoliposomal irinotecan (Nal-Iri) and 5-fluorouracil (5FU)/folinic acid (FA) in patients with advanced pancreatic adenocarcinoma and cachexia who have failed gemcitabine-based chemotherapy... Bermekimab, nano-liposomal irinotecan and 5-fluorouracil in refractory pancreatic cancer patients with cachexia was well-tolerated with promising efficacy and improvements in patient performance. Research Funding: Ipsen
    Clinical • P1 data • Combination therapy
    |
    IL1A (Interleukin 1, alpha)
    |
    gemcitabine • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical • Hutruo (bermekimab IV)
    almost5years
    A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX). (ASCO-GI 2020)
    The present study aims to establish the safety of an IL-1α antagonist (Bermekimab) in combination with nanoliposomal irinotecan (Nal-Iri) and 5-fluorouracil (5FU)/folinic acid (FA) in patients with advanced pancreatic adenocarcinoma and cachexia who have failed gemcitabine-based chemotherapy. Clinical trial information: NCT03207724. Research Funding: Ipsen and XBiotech, Inc
    Clinical • P1 data • Combination therapy
    |
    IL1A (Interleukin 1, alpha)
    |
    gemcitabine • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Hutruo (bermekimab IV)